Apeiron Biologics AG, of Vienna, Austria, and the Cleveland Clinic Foundation, of Cleveland, have agreed to collaborate on anticancer compounds currently in development at the clinic. The collaboration includes an option to Apeiron to enter a worldwide, exclusive license agreement with the clinic relating to the compounds, and an Apeiron-sponsored research agreement with the clinic relating to those compounds and approach, the company said.